Search


Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuff™ and First Aid Kit… learn more »

Kogenate FS Logo - antihemophilic factor (recombinant) for the treatment of Hemophilia A

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. Continue Reading Below »

Insurance Information (Bayer HealthCare Factor Solutions)

Worried about Insurance Coverage? Bayer HealthCare’s Factor Solutions program can provide factor support during loss of insurance* to ensure you receive your Kogenate® FS, antihemophilic factor (recombinant) with BIO-SET® treatment.

Designed for convenience, Bayer HealthCare’s Factor Solutions program can help with:

  • Loss of insurance due to job changes
  • Coverage gaps while changing insurance plans
  • Insurance that doesn’t cover a specific rFVIII
  • Lifetime caps on medical benefits

Factor Solutions: 1-800-288-8374

Easy-to-complete applications:

*Based on determination of program eligibility: terms and conditions apply. The medication provided through this program is complimentary and it is not an obligation to purchase or use Kogenate FS in the future. Reselling or billing any third-party for the free product provided is prohibited by law.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.
BAYER, the Bayer Cross, and KOGENATE are registered trademarks of Bayer.
BIO-SET is a trademark of Biodome SAS.

Bayer HealthCare Pharmaceuticals

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System